Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04175392 · ClinicalTrials.gov registry record · Phase 1
Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis
A Phase 1 study, sponsored by Corewell Health East.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT04175392 is a Phase 1 study that was terminated before completion, run by Corewell Health East. The registered enrollment target is 14 participants.
The verdict
NCT04175392, a Phase 1 study, was terminated before completion, sponsored by Corewell Health East.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study will evaluate the effect of probiotics, a beneficial intestinal bacteria supplement, if it will cause improvement of the non-alcoholic fatty liver disease (NAFLD) and or non-alcoholic steatohepatitis (NASH- an inflammation with concurrent fatty accumulation of the liver) as measured by transient elastography - an ultrasound of the liver that assess the elastic properties (density) and stiffness of the liver tissue. This study will enroll patients 18 years and older with diagnosis of NAFLD and or NASH.
Interventions
- DRUG Placebos
- DRUG Align Probiotic Supplement Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-01-12 |
| Est. Completion | 2022-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04175392
The ClinicalTrials.gov registry entry for NCT04175392 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corewell Health East, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT04175392 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04175392 about?
NCT04175392 is a clinical study titled "Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis". This study will evaluate the effect of probiotics, a beneficial intestinal bacteria supplement, if it will cause improvement of the non-alcoholic fatty liver disease (NAFLD) and or non-alcoholic steatohepatitis (NASH- an inflammation with concurrent fatty accumulation of the liver) as measured by tr...
What is the current status of trial NCT04175392?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2021-01-12. Estimated completion is 2022-03-01.
What interventions are being tested in trial NCT04175392?
The interventions under investigation include: Placebos (DRUG), Align Probiotic Supplement Capsule (DRUG).
Who is sponsoring clinical trial NCT04175392?
This trial is sponsored by Corewell Health East, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.